Reparative Calcified Barrier Characterization after Mixing Injectable-Platelet Rich Fibrin with Bioactive Direct Pulp Capping Agents; An Exp. Study.

Abstract

Aim: This study investigated the morphology and localization of hard tissue barriers formed after direct pulp capping using i-PRF mixed with bioactive agents (Mineral Trioxide Aggregate (MTA) and Bioactive Bone Graft (BBG)) in dogs' teeth using Scanning Electron Microscope. Materials and methods: A total of 64 teeth were used out of 8 healthy male mongrel dogs. The teeth were randomly assigned into four groups according to capping agents used, they were exposed and capped as follow, Group A; capped with MTA, Group B; capped with MTA+ i-PRF, Group C; capped with BBG, Group D; capped with BBG + i-PRF. Finally the access cavity was restored with Intermediate Restorative Material (IRM). The dogs were euthanized after 1 month; and samples were then prepared for scanning electron microscopic study. SEM was used to assess the morphology, localization and extension of the reparative hard tissue barriers and using an image-processing and analysis software to delimit the perimeters of the root canal area and the hard tissue barrier to determine the percentage of root canal obliteration. Chi-square test was used for intragroup comparisons. Results showed that all groups were statistically different (P < 0.05), regarding tissue barrier morphology. Conclusion: Addition of i-PRF to pulp capping agents allows production of peripheral hard tissue barriers with more dentinal tubules.

Pioneering Periapical Healing: The Novel Synergy of Mineral Trioxide Aggregate and Injectable Platelet-Rich Fibrin

“…The obtained i-PRF in light yellow color was then extracted in the syringe containing MTA, lightly mixed, and placed in the periapical area of tooth 12. Subsequently, the canal was obturated using MTA mixed with i-PRF [ 14 ] in a wet sand consistency. The post-endodontic restoration was carried out using composite resin (3M Z250 XT, 3M, USA), and an IOPA radiograph was taken (Figure 5 ).…”

“…As i-PRF is recognized for its sustained release of growth factors over a period of approximately 10 days [ 14 ], the patient was recalled after 10 days. During this appointment, a fresh mixture of MTA and i-PRF was prepared using the same established protocol as previously mentioned.…”